Suppr超能文献

应用诺如病毒感染患者血清样本鉴定 GII.4 和 GII.17 诺如病毒之间的抗原相关性。

Characterization of Antigenic Relatedness between GII.4 and GII.17 Noroviruses by Use of Serum Samples from Norovirus-Infected Patients.

机构信息

Department of Epidemiology, School of Public Health, Southern Medical University (Guangdong Provincial Key Laboratory of Tropical Disease Research), Guangzhou, Guangdong, China.

Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

出版信息

J Clin Microbiol. 2017 Dec;55(12):3366-3373. doi: 10.1128/JCM.00865-17. Epub 2017 Sep 13.

Abstract

A novel GII.17 norovirus variant caused major gastroenteritis epidemics in China in 2014 to 2016. To explore the host immune factors in selection of the emergence of this new variant, we characterized its antigenic relatedness with the GII.4 noroviruses that have dominated in China for decades. Through an enzyme-linked immunosorbent assay (ELISA) and a histo-blood group antigen (HBGA) blocking assay using sera from GII.4 and the GII.17 variant-infected patients, respectively, we observed limited cross-immune reactivity by the ELISA but little reactivity by the HBGA blocking assay between GII.4 norovirus and the new GII.17 variant. Our data suggest that, among other possible factors, GII.4-specific herd immunity had little role in the emergence of the new GII.17 variant. Thus, GII.17 may be an important active antigenic type or immunotype that needs to be considered for future vaccine strategies against human noroviruses.

摘要

一种新型的 GII.17 诺如病毒变异株在 2014 年至 2016 年期间引发了中国的重大胃肠炎疫情。为了探索宿主免疫因素在这种新变异株出现中的选择作用,我们对其与在中国流行了几十年的 GII.4 诺如病毒的抗原相关性进行了表征。通过酶联免疫吸附试验(ELISA)和使用来自 GII.4 和 GII.17 变异株感染患者的血清进行的组织血型抗原(HBGA)阻断试验,我们观察到 ELISA 之间的交叉免疫反应有限,但 HBGA 阻断试验之间的反应很少。我们的数据表明,在其他可能的因素中,GII.4 特异性群体免疫在新的 GII.17 变异株的出现中作用不大。因此,GII.17 可能是一种重要的活性抗原类型或免疫型,需要考虑用于未来针对人类诺如病毒的疫苗策略。

相似文献

2
Antigenic Relatedness of Norovirus GII.4 Variants Determined by Human Challenge Sera.
PLoS One. 2015 Apr 27;10(4):e0124945. doi: 10.1371/journal.pone.0124945. eCollection 2015.
6
Development of a broad-spectrum therapeutic Fc-nanobody for human noroviruses.
J Virol. 2024 Jul 23;98(7):e0070724. doi: 10.1128/jvi.00707-24. Epub 2024 Jul 2.
7
8
Human Norovirus Neutralized by a Monoclonal Antibody Targeting the Histo-Blood Group Antigen Pocket.
J Virol. 2019 Feb 19;93(5). doi: 10.1128/JVI.02174-18. Print 2019 Mar 1.

引用本文的文献

1
Detection of IgG antibody against the porcine norovirus GII.11 in human, domestic and wild animals.
Front Microbiol. 2025 Jun 26;16:1567132. doi: 10.3389/fmicb.2025.1567132. eCollection 2025.
2
Vaccinia Virus Vector Bivalent Norovirus Vaccine.
Viruses. 2025 Feb 9;17(2):237. doi: 10.3390/v17020237.
3
Norovirus replication, host interactions and vaccine advances.
Nat Rev Microbiol. 2025 Jun;23(6):385-401. doi: 10.1038/s41579-024-01144-9. Epub 2025 Jan 17.
4
Serological surveillance of GI norovirus reveals persistence of blockade antibody in a Jidong community-based prospective cohort, 2014-2018.
Front Cell Infect Microbiol. 2023 Dec 18;13:1258550. doi: 10.3389/fcimb.2023.1258550. eCollection 2023.
6
Identification and genetic characterization of a minor norovirus genotype, GIX.1[GII.P15], from China.
BMC Genom Data. 2022 Jul 6;23(1):50. doi: 10.1186/s12863-022-01066-6.
7
Epidemiology and evolution of Norovirus in China.
Hum Vaccin Immunother. 2021 Nov 2;17(11):4553-4566. doi: 10.1080/21645515.2021.1961465. Epub 2021 Sep 8.
8
Evolutionary Mechanism of Immunological Cross-Reactivity Between Different GII.17 Variants.
Front Microbiol. 2021 Apr 6;12:653719. doi: 10.3389/fmicb.2021.653719. eCollection 2021.
9
Understanding the relationship between norovirus diversity and immunity.
Gut Microbes. 2021 Jan-Dec;13(1):1-13. doi: 10.1080/19490976.2021.1900994.
10
Serological surveillance of noroviruses in a community-based prospective cohort: a study protocol.
BMJ Open. 2021 Mar 4;11(3):e043228. doi: 10.1136/bmjopen-2020-043228.

本文引用的文献

1
Global Spread of Norovirus GII.17 Kawasaki 308, 2014-2016.
Emerg Infect Dis. 2017 Aug;23(8):1359-1354. doi: 10.3201/eid2308.161138.
2
Emergence of new recombinant noroviruses GII.p16-GII.4 and GII.p16-GII.2, France, winter 2016 to 2017.
Euro Surveill. 2017 Apr 13;22(15). doi: 10.2807/1560-7917.ES.2017.22.15.30508.
3
Norovirus GII.P16/GII.2-Associated Gastroenteritis, China, 2016.
Emerg Infect Dis. 2017 Jul;23(7):1172-1175. doi: 10.3201/eid2307.170034. Epub 2017 Jul 15.
4
Association of GII.P16-GII.2 Recombinant Norovirus Strain with Increased Norovirus Outbreaks, Guangdong, China, 2016.
Emerg Infect Dis. 2017 Jul;23(7):1188-1190. doi: 10.3201/eid2307.170333. Epub 2017 Jul 15.
5
Static and Evolving Norovirus Genotypes: Implications for Epidemiology and Immunity.
PLoS Pathog. 2017 Jan 19;13(1):e1006136. doi: 10.1371/journal.ppat.1006136. eCollection 2017 Jan.
6
Recurrent Infections of Emergent Norovirus GII.17 in an Elderly.
Clin Infect Dis. 2017 Mar 1;64(5):697-699. doi: 10.1093/cid/ciw822. Epub 2016 Dec 12.
7
Characterization of the new GII.17 norovirus variant that emerged recently as the predominant strain in China.
J Gen Virol. 2016 Oct;97(10):2620-2632. doi: 10.1099/jgv.0.000582. Epub 2016 Aug 18.
8
The Evolution and Transmission of Epidemic GII.17 Noroviruses.
J Infect Dis. 2016 Aug 15;214(4):556-64. doi: 10.1093/infdis/jiw208. Epub 2016 May 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验